top of page


P R E F U S I O N   R S V  F   P RO T E I N


14 March 2024

Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages. Gidwani, S.V., Brahmbhatt, D., Zomback, A. et al. Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages. Nat Commun 15, 2202 (2024). DOI:

October 4, 2022

Prior respiratory syncytial virus infection reduces vaccine- mediated Th2-skewed immunity, but retains enhanced RSV F-specific CD8 T cell responses elicited by a Th1- skewing vaccine formulation

Katherine M. Eichinger, Jessica L. Kosanovich, Timothy N. Perkins, Tim D. Oury, Nikolai Petrovsky, Christopher P. Marshall, Mark A. Yondola, Kerry M. Empey.

Frontiers in Immunology. 2022 Oct 04;11:1673. DOI:

August 20, 2020

Formulation of the prefusion RSV F protein with a Th1/Th2-balanced adjuvant provides complete protection without Th2-skewed immunity in RSV-experienced young mice.

Kosanovich JL, Eichinger KM, Lipp MA, Yondola MA, Perkins TN, Empey KM.

Vaccine. 2020 Sep 22;38(41):6357-6362. doi: 10.1016/j.vaccine.2020.08.023. Epub 2020 Aug 20.

PMID: 32829976 PMCID: PMC7540734 (2021-09-22)​  DOI: 10.1016/j.vaccine.2020.08.023

Nov 2020 

Maternal immunization with adjuvanted RSV prefusion F protein effectively protects offspring from RSV challenge and alters innate and T cell immunity.  2020 Nov.  Eichinger KM, Kosanovich JL, Lipp MA, Perkins TN, Petrovsky N, Marshall C, Yondola MA, Empey KM. Vaccine 38(50):7885-7891. PMID: 33129608 DOI: 10.1016/j.vaccine.2020.10.065

Jul 2020

Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection.  2020 Jul.  Eichinger KM, Kosanovich JL, Gidwani SV, Zomback A, Lipp MA, Perkins TN, Oury TD, Petrovsky N, Marshall CP, Yondola MA, Empey KM.

Frontiers in Immunology 11:1673. PMID: 32849580  PMCID: PMC7403488​  DOI: 10.3389/fimmu.2020.01673


S T A B I L I Z E D   P R O T E I N   E N G I N E E R I N G

Feb 6, 2019

Calder Biosciences: Engineering Solutions for Improved Vaccines

Scientia. 2019 Feb 6. Biology, Health and Medicine


U N I V E R S A L   I N F L U E N Z A

May 4, 2015

Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.

Leyva-Grado VH, Tan GS, Leon PE, Yondola M, Palese P.

Antimicrobial Agents and Chemotherapy. 2015 Jul;59(7):4162-72. doi: 10.1128/AAC.00290-15. Epub 2015 May 4.

PMID: 25941218  PMCID: PMC4468714​  DOI: 10.1128/AAC.00290-15

Jan 8, 2014

Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.

Krammer F, Hai R, Yondola M, Tan GS, Leyva-Grado VH, Ryder AB, Miller MS, Rose JK, Palese P, García-Sastre A, Albrecht RA.

Journal of Virology. 2014 Mar;88(6):3432-42. doi: 10.1128/JVI.03004-13. Epub 2014 Jan 8.

PMID: 24403585  PMCID: PMC3957929​  DOI: 10.1128/JVI.03004-13

Dec 29, 2013

Modulation of an ectodomain motif in the influenza A virus neuraminidase alters tetherin sensitivity and results in virus attenuation in vivo.

Leyva-Grado VH, Hai R, Fernandes F, Belicha-Villanueva A, Carter C, Yondola MA.

Journal of Molecular Biology. 2014 Mar 20;426(6):1308-21. Epub 2013 Dec 29.

PMID: 24380762 PMCID: PMC3963499​  DOI: 10.1016/j.jmb.2013.12.023

Jan 5, 2011

Budding capability of the influenza virus neuraminidase can be modulated by tetherin.

Yondola MA, Fernandes F, Belicha-Villanueva A, Uccelini M, Gao Q, Carter C, Palese P.

Journal of Virology. 2011 Mar;85(6):2480-91. doi: 10.1128/JVI.02188-10. Epub 2011 Jan 5.

PMID: 21209114  PMCID: PMC3067929​  DOI: 10.1128/JVI.02188-10

Jan 3, 2011

Un-“ESCRT”-ed budding.

Yondola M, Carter C.

Virus. 2011 Jan;3(1):26-31. doi: 10.3390/v3010026.

PMID: 21666754  PMCID: PMC3110670  DOI: 10.3390/v3010026

May 18, 2010

Influenza virus vaccine based on the conserved hemagglutinin stalk domain.

Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, García-Sastre A, Palese P.

mBio. American Society for Microbiology. 2010 May 18;1(1):e00018-10. doi: 10.1128/mBio.00018-10.

PMID: 20689752  PMCID: PMC2912658​  DOI: 10.1128/mBio.00018-10


A D E N O V I R U S   E 4 - O R F 3

May 9, 2012

Biophysical and functional analyses suggest that adenovirus E4-ORF3 protein requires higher-order multimerization to function against promyelocytic leukemia protein nuclear bodies.

Patsalo V, Yondola MA, Luan B, Shoshani I, Kisker C, Green DF, Raleigh DP, Hearing P.

Journal of Biological Chemistry. 2012 Jun 29;287(27):22573-83. doi: 10.1074/jbc.M112.344234. Epub 2012 May 9.

PMID: 22573317 PMCID: PMC3391147​  DOI: 10.1074/jbc.M112.344234

Nov 27, 2011

Adenovirus E4-ORF3-dependent relocalization of TIF1α and TIF1γ relies on access to the Coiled-Coil motif.

Vink EI, Yondola MA, Wu K, Hearing P.

Virology. 2012 Jan 20;422(2):317-25. doi: 10.1016/j.virol.2011.10.033. Epub 2011 Nov 27.

PMID: 22123502  PMCID: PMC3249475​  DOI: 10.1016/j.virol.2011.10.033


Feb 7, 2007

The adenovirus E4 ORF3 protein binds and reorganizes the TRIM family member transcriptional intermediary factor 1 alpha.

Yondola MA, Hearing P.

Journal of Virology. 2007 Apr;81(8):4264-71. doi: 10.1128/JVI.02629-06. Epub 2007 Feb 7.

PMID: 17287283  PMCID: PMC1866117​  DOI: 10.1128/JVI.02629-06

bottom of page